Analyst Naz Rahman from Maxim Group reiterated a Buy rating on scPharmaceuticals and keeping the price target at $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Naz Rahman has given his Buy rating due to a combination of factors including scPharmaceuticals’ impressive financial performance and strategic initiatives. The company reported a significant increase in revenue for the second quarter of 2025, surpassing both consensus and internal estimates, which indicates strong market demand and effective sales strategies. Additionally, the launch of Furoscix for Chronic Kidney Disease (CKD) is progressing well, with early signs of success exceeding those of the initial heart failure launch.
Another factor contributing to the Buy rating is the anticipated positive impact of recent Medicare Part D changes and the potential benefits from the CMS Ambulatory Specialty Model proposal, which could further drive Furoscix’s growth. The upcoming submission of the sNDA for the auto-injector is expected to enhance gross margins significantly upon approval. Overall, the combination of these developments, along with narrowing net losses and projected breakeven by 2026, supports a positive outlook for scPharmaceuticals, justifying the Buy rating.
In another report released yesterday, Craig-Hallum also reiterated a Buy rating on the stock with a $12.00 price target.